HER2 Support Group Forums - View Single Post

06-15-2005, 08:23 AM

http://www.smartmoney.com/stockwatch/index...?story=20050614

"Hauber suggests that some products toward the end of the GSK pipeline, including the breast and lung cancer drug Lapatinib, could be prone to setbacks because they were rushed through earlier research stages. She wrote that "significant miscalculations were made" in the development of Lapatinib and that "marketing considerations appear to have overruled preclinical insights, and Phase III trials were begun before data from (failed) pivotal Phase II studies became available." Her conclusion: "Ongoing Phase III studies have high risk of failure in our view, suggesting that the current submission target (2006/07) is too ambitious. Lapatinib may not reach the market in this decade." That would be a large blow to the GSK pipeline and to the company in general. "

06-15-2005, 08:23 AM	#1
Rich Guest Posts: n/a	http://www.smartmoney.com/stockwatch/index...?story=20050614 "Hauber suggests that some products toward the end of the GSK pipeline, including the breast and lung cancer drug Lapatinib, could be prone to setbacks because they were rushed through earlier research stages. She wrote that "significant miscalculations were made" in the development of Lapatinib and that "marketing considerations appear to have overruled preclinical insights, and Phase III trials were begun before data from (failed) pivotal Phase II studies became available." Her conclusion: "Ongoing Phase III studies have high risk of failure in our view, suggesting that the current submission target (2006/07) is too ambitious. Lapatinib may not reach the market in this decade." That would be a large blow to the GSK pipeline and to the company in general. "